These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 9705598)
1. Azathioprine in inflammatory bowel disease, a safe alternative? Tanis AA Mediators Inflamm; 1998; 7(3):141-4. PubMed ID: 9705598 [TBL] [Abstract][Full Text] [Related]
2. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279 [TBL] [Abstract][Full Text] [Related]
3. Adverse effects of azathioprine in the treatment of inflammatory bowel disease. Martínez F; Nos P; Pastor M; Garrigues V; Ponce J Rev Esp Enferm Dig; 2001 Dec; 93(12):769-78. PubMed ID: 11995359 [TBL] [Abstract][Full Text] [Related]
4. Toxicity of 6-mercaptopurine/azathioprine in patients with inflammatory bowel disease. Marion JF Inflamm Bowel Dis; 1998 May; 4(2):116-7. PubMed ID: 9687219 [No Abstract] [Full Text] [Related]
5. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Lees CW; Maan AK; Hansoti B; Satsangi J; Arnott ID Aliment Pharmacol Ther; 2008 Feb; 27(3):220-7. PubMed ID: 17988235 [TBL] [Abstract][Full Text] [Related]
6. Desensitization of patients with allergic reactions to immunosuppressives in the treatment of inflammatory bowel disease. Korelitz BI; Reddy B; Bratcher J Expert Opin Drug Saf; 2010 May; 9(3):379-82. PubMed ID: 20367524 [TBL] [Abstract][Full Text] [Related]
7. [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects]. Schwab M; Herrlinger K; Schaeffeler E; Stange EF Dtsch Med Wochenschr; 2003 Feb; 128(8):378-85. PubMed ID: 12594624 [No Abstract] [Full Text] [Related]
8. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Bajaj JS; Saeian K; Varma RR; Franco J; Knox JF; Podoll J; Emmons J; Levy M; Binion DG Am J Gastroenterol; 2005 May; 100(5):1121-5. PubMed ID: 15842588 [TBL] [Abstract][Full Text] [Related]
9. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Su C; Lichtenstein GR Gastroenterol Clin North Am; 2004 Jun; 33(2):209-34, viii. PubMed ID: 15177535 [TBL] [Abstract][Full Text] [Related]
10. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Gearry RB; Barclay ML; Burt MJ; Collett JA; Chapman BA Pharmacoepidemiol Drug Saf; 2004 Aug; 13(8):563-7. PubMed ID: 15317038 [TBL] [Abstract][Full Text] [Related]
11. Erythema nodosum-like eruption as a manifestation of azathioprine hypersensitivity in patients with inflammatory bowel disease. de Fonclare AL; Khosrotehrani K; Aractingi S; Duriez P; Cosnes J; Beaugerie L Arch Dermatol; 2007 Jun; 143(6):744-8. PubMed ID: 17576940 [TBL] [Abstract][Full Text] [Related]
12. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828 [TBL] [Abstract][Full Text] [Related]
13. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564 [TBL] [Abstract][Full Text] [Related]
14. Thiopurine therapy: when to start and when to stop. McGovern DP; Travis SP Eur J Gastroenterol Hepatol; 2003 Mar; 15(3):219-23. PubMed ID: 12610314 [TBL] [Abstract][Full Text] [Related]
15. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. Hibi T; Naganuma M; Kitahora T; Kinjyo F; Shimoyama T J Gastroenterol; 2003; 38(8):740-6. PubMed ID: 14505127 [TBL] [Abstract][Full Text] [Related]
16. Review article: Reproduction in the patient with inflammatory bowel disease. Heetun ZS; Byrnes C; Neary P; O'Morain C Aliment Pharmacol Ther; 2007 Aug; 26(4):513-33. PubMed ID: 17661756 [TBL] [Abstract][Full Text] [Related]
17. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Hindorf U; Lindqvist M; Hildebrand H; Fagerberg U; Almer S Aliment Pharmacol Ther; 2006 Jul; 24(2):331-42. PubMed ID: 16842460 [TBL] [Abstract][Full Text] [Related]
18. A triangulation study of the clinician and patient experiences of the use of the immunosuppressant drugs azathioprine and 6-mercaptopurine for the management of inflammatory bowel disease. Holbrook K J Clin Nurs; 2007 Aug; 16(8):1427-34. PubMed ID: 17655530 [TBL] [Abstract][Full Text] [Related]
19. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Hindorf U; Johansson M; Eriksson A; Kvifors E; Almer SH Aliment Pharmacol Ther; 2009 Mar; 29(6):654-61. PubMed ID: 19183142 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn's disease. Markowitz JF Rev Gastroenterol Disord; 2003; 3 Suppl 1():S23-9. PubMed ID: 12684586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]